TherapeuticsMD (TXMD) Common Equity (2010 - 2026)

TherapeuticsMD has reported Common Equity for 17 years, with the latest figure at $27.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 0.87% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $27.0 million (up 0.87% YoY), and the FY2025 full-year result was $26.9 million, down 1.8% from the prior year.
• Common Equity for Q1 2026 stood at $27.0 million, roughly flat from $26.9 million in the prior quarter.
• The five-year high for Common Equity was $35.1 million in Q4 2022, with the low at -$140.6 million in Q1 2022.
• Historically, Common Equity has averaged $11.0 million across 5 years, with a median of $27.4 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity tumbled 1383.22% — and 2023, when it soared 219.68%.
• TherapeuticsMD's Common Equity stood at $35.1 million in 2022, then retreated by 16.66% to $29.3 million in 2023, then retreated by 6.55% to $27.4 million in 2024, then decreased by 1.8% to $26.9 million in 2025, then gained by 0.36% to $27.0 million in 2026.
• The last three Common Equity figures came in at $27.0 million (Q1 2026), $26.9 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.